ANPEP and Duchenne muscular dystrophy: Exogenously administered agonists of adiponectin (ApN) and its downstream cell-surface receptors have emerged as an attractive candidate for pharmacological intervention given their anti-inflammatory properties in DMD [17,18,19,20,21,22] and ability to induce metabolic reprogramming in muscle [10,23,24,25,26,27,28,29].